A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Burnett, Alan Kenneth, Milligan, Donald, Prentice, Archie G., Goldstone, Anthony H., McMullin, Mary F., Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062 and Wheatley, Keith 2007. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109 (6) , pp. 1114-1124. 10.1002/cncr.22496

Full text not available from this repository.

Abstract

n this study, patients with acute myeloid leukemia or high-risk myelodysplastic syndrome who were unfit for intensive chemotherapy were randomized to receive either low-dose cytarabine (ara-C) or hydroxyurea with or without all-trans retinoic acid. The results indicted that low-dose ara-C was superior to best supportive care and hydroxyurea and may represent standard care against which new treatments are compared in this patient group.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher:	Wiley-Blackwell
ISSN:	0008-543X
Last Modified:	24 Oct 2022 11:55
URI:	https://orca.cardiff.ac.uk/id/eprint/49736

Citation Data

Cited 520 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item